Cargando…
A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is recognized as a classic clonal myeloproliferative disorder. Given the limited treatment options for CML patients in the accelerated phase (AP) and blast phase (BP), there is an evident need to develop new therapeutic strategies. This has the potential to improve out...
Autores principales: | Chen, Mengting, Fang, Xiaocui, Du, Rong, Meng, Jie, Liu, Jingyi, Liu, Mingpeng, Yang, Yanlian, Wang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534672/ https://www.ncbi.nlm.nih.gov/pubmed/37765274 http://dx.doi.org/10.3390/pharmaceutics15092305 |
Ejemplares similares
-
Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5
por: Fang, Xiaocui, et al.
Publicado: (2017) -
A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia
por: Xu, Shilin, et al.
Publicado: (2021) -
Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications
por: Liu, Mingpeng, et al.
Publicado: (2021) -
Complex polymeric nanomicelles co-delivering doxorubicin and dimethoxycurcumin for cancer chemotherapy
por: Sohail, Muhammad, et al.
Publicado: (2022) -
Systemic delivery of the anticancer agent arenobufagin using polymeric nanomicelles
por: Yuan, Xue, et al.
Publicado: (2017)